| Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study T Nyberg, NM Ferguson, SG Nash, HH Webster, S Flaxman, N Andrews, ... The Lancet 399 (10332), 1303-1312, 2022 | 605 | 2022 |
| Isaac Newton Institute IID collaboration (2015) Modelling infectious disease dynamics in the complex landscape of global health H Heesterbeek, RM Anderson, V Andreasen, S Bansal, D De Angelis, ... Science 347, 6227, 0 | 600* | |
| Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 565 | 2022 |
| The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence KME Turner, S Hutchinson, P Vickerman, V Hope, N Craine, N Palmateer, ... Addiction 106 (11), 1978-1988, 2011 | 405 | 2011 |
| The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis AM Presanis, D De Angelis, ... PLoS medicine 6 (12), e1000207, 2009 | 377 | 2009 |
| Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment J Kimber, L Copeland, M Hickman, J Macleod, J McKenzie, D De Angelis, ... Bmj 341, 2010 | 224 | 2010 |
| Modeling the percolation of annotation errors in a database of protein sequences WR Gilks, B Audit, D De Angelis, S Tsoka, CA Ouzounis Bioinformatics 18 (12), 1641-1649, 2002 | 205 | 2002 |
| A Markov model for HIV disease progression including the effect of HIV diagnosis and treatment: application to AIDS prediction in England and Wales OO Aalen, VT Farewell, D de Angelis, NE Day, O Nöel Gill Statistics in medicine 16 (19), 2191-2210, 1997 | 173 | 1997 |
| Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model MJ Price, AE Ades, D De Angelis, NJ Welton, J Macleod, K Soldan, ... American journal of epidemiology 178 (3), 484-492, 2013 | 170 | 2013 |
| HIV incidence in men who have sex with men in England and Wales 2001–10: a nationwide population study PJ Birrell, ON Gill, VC Delpech, AE Brown, S Desai, TR Chadborn, ... The Lancet infectious diseases 13 (4), 313-318, 2013 | 161 | 2013 |
| Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS … A Babiker, S Darby, D De Angelis, D Kwart, K Porter, V Beral, ... Lancet 355 (9210), 2000 | 143 | 2000 |
| Bayesian modeling to unmask and predict influenza A/H1N1pdm dynamics in London PJ Birrell, G Ketsetzis, NJ Gay, BS Cooper, AM Presanis, RJ Harris, ... Proceedings of the National Academy of Sciences 108 (45), 18238-18243, 2011 | 142 | 2011 |
| HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact NK Martin, GR Foster, J Vilar, S Ryder, M E Cramp, F Gordon, JF Dillon, ... Journal of viral hepatitis 22 (4), 399-408, 2015 | 123 | 2015 |
| Risk of hospital admission for patients with SARS-CoV-2 variant B. 1.1. 7: cohort analysis T Nyberg, KA Twohig, RJ Harris, SR Seaman, J Flannagan, H Allen, ... bmj 373, 2021 | 122 | 2021 |
| Estimating HIV incidence, time to diagnosis, and the undiagnosed HIV epidemic using routine surveillance data A van Sighem, F Nakagawa, D De Angelis, C Quinten, D Bezemer, ... Epidemiology (Cambridge, Mass.) 26 (5), 653, 2015 | 115 | 2015 |
| Assessing the impact of national anti-HIV sexual health campaigns: trends in the transmission of HIV and other sexually transmitted infections in England A Nicoll, G Hughes, M Donnelly, S Livingstone, D De Angelis, K Fenton, ... Sexually Transmitted Infections 77 (4), 242-247, 2001 | 114 | 2001 |
| Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis RJ Harris, M Ramsay, VD Hope, L Brant, M Hickman, GR Foster, ... The European Journal of Public Health 22 (2), 187-192, 2012 | 111 | 2012 |
| Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under … RJ Harris, B Thomas, J Griffiths, A Costella, R Chapman, M Ramsay, ... Journal of hepatology 61 (3), 530-537, 2014 | 106 | 2014 |
| HCV Treatment as Prevention in People Who Inject Drugs–testing the evidence M Hickman, D De Angelis, P Vickerman, S Hutchinson, N Martin Current opinion in infectious diseases 28 (6), 576, 2015 | 105 | 2015 |
| Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths D De Angelis, M Hickman, S Yang American Journal of Epidemiology 160 (10), 994-1004, 2004 | 100 | 2004 |
Anne M PresanisMRC Biostatistics Unit, University of CambridgeBestätigte E-Mail-Adresse bei mrc-bsu.cam.ac.uk
